Skip to content
Login Register

#CD30

2 public questions tagged with this topic.

Immunological Applications

Brentuximab vedotin targets:

CD30 antigen also designated TNFRSF8, 120 kDa type I transmembrane glycoprotein member tumor necrosis factor receptor superfamily characterized by cysteine rich domains extracellularly and TRAF binding motifs intracellularly activating NF-kB, transiently expressed on activated B and T lymphocytes but constitutively highly expressed on Reed-Sternberg giant cells of classical Hodgkin lymphoma and anaplastic large cell lymphoma ALCL, and small subset cutaneous T cell lymphomas, making near tumor specific target with minimal normal tissue expression limited to activated immune cells conferring fav

Ref: Younes et al NEJM 2010 363:1812 Brentuximab vedotin CD30 MMAE valine citrulline; Seattle Genetics Adcetris approval.

View Details
Immunological Applications

Brentuximab vedotin targets:

Brentuximab vedotin Adcetris exemplifies first approved CD30-directed antibody-drug conjugate transforming management Hodgkin lymphoma systemic anaplastic large cell lymphoma peripheral T-cell lymphoma uniformly expressing CD30 TNFRSF8 120 kDa type I transmembrane signaling TRAF1 TRAF2 TRAF5 activating NF-kB MAPK promoting survival malignant clone. Murine chimeric cAC10 IgG1 human constant murine variable binds ECD residues 19-38 affinity 5 nM complex rapidly internalizes 2-4h CD30-mediated clathrin-dependent endocytosis delivering conjugate lysosomal compartment acidic pH proteases degrade an

Ref: FDA Adcetris Brentuximab Vedotin CD30 Target Label Mechanism; NEJM Brentuximab Hodgkin Lymphoma Efficacy 2012 Younes et al; Trail ADC CD30 Mechanism Review.

View Details